AiCuris GmbH & Co. KG – Product Pipeline Review

Global Markets Direct’s, ‘AiCuris GmbH & Co. KG – Product Pipeline Review – 2016’, provides an overview of the AiCuris GmbH & Co. KG’s pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by AiCuris GmbH & Co. KG, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the pipeline therapeutic landscape of AiCuris GmbH & Co. KG

The report provides overview of AiCuris GmbH & Co. KG including its business description, key facts, and locations and subsidiaries

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report assesses AiCuris GmbH & Co. KG’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report features AiCuris GmbH & Co. KG’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

Evaluate AiCuris GmbH & Co. KG’s strategic position with total access to detailed information on its product pipeline

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for AiCuris GmbH & Co. KG

Identify potential new clients or partners in the target demographic

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding AiCuris GmbH & Co. KG’s pipeline depth and focus of pipeline therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

AiCuris GmbH & Co. KG Snapshot 5

AiCuris GmbH & Co. KG Overview 5

Key Information 5

Key Facts 5

AiCuris GmbH & Co. KG - Research and Development Overview 6

Key Therapeutic Areas 6

AiCuris GmbH & Co. KG - Pipeline Review 9

Pipeline Products by Stage of Development 9

Pipeline Products - Monotherapy 10

Pipeline Products - Out-Licensed Products 11

Out-Licensed Products/Combination Treatment Modalities 12

AiCuris GmbH & Co. KG - Pipeline Products Glance 13

AiCuris GmbH & Co. KG - Clinical Stage Pipeline Products 13

Phase II Products/Combination Treatment Modalities 13

Phase I Products/Combination Treatment Modalities 14

AiCuris GmbH & Co. KG - Early Stage Pipeline Products 15

Preclinical Products/Combination Treatment Modalities 15

Discovery Products/Combination Treatment Modalities 16

AiCuris GmbH & Co. KG - Drug Profiles 17

pritelivir 17

Product Description 17

Mechanism of Action 17

R&D Progress 17

AIC-284 19

Product Description 19

Mechanism of Action 19

R&D Progress 19

AIC-649 20

Product Description 20

Mechanism of Action 20

R&D Progress 20

AIC-277 21

Product Description 21

Mechanism of Action 21

R&D Progress 21

AIC-499 22

Product Description 22

Mechanism of Action 22

R&D Progress 22

Drug for Infectious Disease 23

Product Description 23

Mechanism of Action 23

R&D Progress 23

Small Molecule 1 for Gram-Negative Bacterial Infections 24

Product Description 24

Mechanism of Action 24

R&D Progress 24

Small Molecule 2 for Gram-Negative Bacterial Infections 25

Product Description 25

Mechanism of Action 25

R&D Progress 25

Small Molecule for Gram-Positive Bacterial Infections 26

Product Description 26

Mechanism of Action 26

R&D Progress 26

Small Molecule for Infectious Disease 27

Product Description 27

Mechanism of Action 27

R&D Progress 27

Small Molecule for Viral Infections 28

Product Description 28

Mechanism of Action 28

R&D Progress 28

AiCuris GmbH & Co. KG - Pipeline Analysis 29

AiCuris GmbH & Co. KG - Pipeline Products by Target 29

AiCuris GmbH & Co. KG - Pipeline Products by Route of Administration 30

AiCuris GmbH & Co. KG - Pipeline Products by Molecule Type 31

AiCuris GmbH & Co. KG - Pipeline Products by Mechanism of Action 32

AiCuris GmbH & Co. KG - Recent Pipeline Updates 33

AiCuris GmbH & Co. KG - Dormant Projects 35

AiCuris GmbH & Co. KG - Locations And Subsidiaries 36

Head Office 36

Appendix 37

Methodology 37

Coverage 37

Secondary Research 37

Primary Research 37

Expert Panel Validation 37

Contact Us 37

Disclaimer 38

List of Tables

List of Tables

AiCuris GmbH & Co. KG, Key Information 5

AiCuris GmbH & Co. KG, Key Facts 5

AiCuris GmbH & Co. KG – Pipeline by Indication, 2016 8

AiCuris GmbH & Co. KG – Pipeline by Stage of Development, 2016 9

AiCuris GmbH & Co. KG – Monotherapy Products in Pipeline, 2016 10

AiCuris GmbH & Co. KG – Out-Licensed Products in Pipeline, 2016 11

AiCuris GmbH & Co. KG – Out-Licensed Products/ Combination Treatment Modalities, 2016 12

AiCuris GmbH & Co. KG – Phase II, 2016 13

AiCuris GmbH & Co. KG – Phase I, 2016 14

AiCuris GmbH & Co. KG – Preclinical, 2016 15

AiCuris GmbH & Co. KG – Discovery, 2016 16

AiCuris GmbH & Co. KG – Pipeline by Target, 2016 29

AiCuris GmbH & Co. KG – Pipeline by Route of Administration, 2016 30

AiCuris GmbH & Co. KG – Pipeline by Molecule Type, 2016 31

AiCuris GmbH & Co. KG – Pipeline Products by Mechanism of Action, 2016 32

AiCuris GmbH & Co. KG – Recent Pipeline Updates, 2016 33

AiCuris GmbH & Co. KG – Dormant Developmental Projects,2016 35

List of Figures

List of Figures

AiCuris GmbH & Co. KG – Pipeline by Top 10 Indication, 2016 7

AiCuris GmbH & Co. KG – Pipeline by Stage of Development, 2016 9

AiCuris GmbH & Co. KG – Monotherapy Products in Pipeline, 2016 10

AiCuris GmbH & Co. KG – Out-Licensed Products in Pipeline, 2016 11

AiCuris GmbH & Co. KG – Pipeline by Target, 2016 29

AiCuris GmbH & Co. KG – Pipeline by Route of Administration, 2016 30

AiCuris GmbH & Co. KG – Pipeline by Top 10 Molecule Type, 2016 31

AiCuris GmbH & Co. KG – Pipeline Products by Mechanism of Action, 2016 32

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports

Analytics by GoSquared